LogicBio Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
LogicBio Therapeutics, Inc. - overview
Established
2014
Location
Lexington, MA, US
Primary Industry
Biotechnology
About
LogicBio Therapeutics, Inc. is a biotechnology company specializing in gene therapies aimed at treating genetic diseases using its proprietary platform technology. Founded in 2014 and headquartered in Lexington, US, LogicBio Therapeutics, Inc. focuses on developing innovative genetic therapies.
The company raised USD 70 mn in an IPO in October 2018 and later secured USD 42 mn in an equity offering in October 2020. Co-founders Adi Barzel and Mark Kay have a history of entrepreneurial experience, while Frederic Chereau serves as the current CEO. LogicBio Therapeutics, Inc. is dedicated to developing gene therapies that target genetic disorders, utilizing its proprietary genome editing technology.
The company's primary focus is on advancing its product pipeline to address rare diseases, leveraging advanced scientific methods to improve treatment outcomes for patients. In the most recent year, LogicBio Therapeutics reported a revenue of USD 5. 41 mn and an EBITDA of USD -38. 36 mn, reflecting ongoing investments in research and development to further its therapeutic offerings.
LogicBio Therapeutics, Inc. aims to expand its product pipeline by introducing new gene therapies designed for rare genetic disorders. The company is targeting expansion into new markets, particularly in Europe and Asia, by 2023. Recent funding from the Trade Sale, amounting to USD 68 mn, will be utilized to accelerate R&D efforts, enhance clinical trials, and support marketing strategies to facilitate entry into these new regions.
Current Investors
OrbiMed Advisors
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy
Website
www.logicbio.com
Company Stage
Acquired
Total Amount Raised
Subscriber access only
LogicBio Therapeutics, Inc. - timeline of key events
LogicBio Therapeutics, Inc. - financials
| Fiscal Year Ended | Dec 30, 2016 | Dec 30, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 |
|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - |
| EBITDA (USD) | - | - | (17,854,000) | - | - | - |
| Operating Income (USD) | (3,400,000) | (5,800,000) | (17,943,000) | - | - | - |
| Operating Margin | - | - | - | - | - | - |
| % EBITDA Margin | - | - | - | - | - | - |
| NET Income (USD) | - | - | (17,621,000) | - | - | - |
| % Net Margin | - | - | - | - | - | - |
LogicBio Therapeutics, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.